SANTEN PHARMACEUTICAL CO., LTD.
🇯🇵Japan
- Country
- 🇯🇵Japan
- Ownership
- Public
- Established
- 1890-01-01
- Employees
- 3.7K
- Market Cap
- $4.5B
- Website
- http://www.santen.co.jp
A Study Assessing Safety and Efficacy of MD-15 Intraocular Lens in Patients With Aphakic Eye After Cataract Surgery
Phase 3
Completed
- Conditions
- Cataract
- Interventions
- Device: MD-15 Intraocular Lens
- First Posted Date
- 2016-09-02
- Last Posted Date
- 2018-02-27
- Lead Sponsor
- Santen Pharmaceutical Co., Ltd.
- Target Recruit Count
- 110
- Registration Number
- NCT02888210
A Study Assessing the Safety and Efficacy of DE-117 in Subjects With POAG or OH Who Are Non-/Low-responders to Latanoprost: FUJI Study
Phase 3
Completed
- Conditions
- Primary Open Angle Glaucoma or Ocular Hypertension
- Interventions
- Drug: DE-117 ophthalmic solution
- First Posted Date
- 2016-07-04
- Last Posted Date
- 2017-11-20
- Lead Sponsor
- Santen Pharmaceutical Co., Ltd.
- Target Recruit Count
- 26
- Registration Number
- NCT02822742
A Long-term Study of DE-117 Ophthalmic Solution Monotherapy and Concomitant Use of DE-117 Ophthalmic Solution With Timolol Ophthalmic Solution in Patients With OAG or OH: RENGE Study
Phase 3
Completed
- Conditions
- Open Angle Glaucoma or Ocular Hypertension
- Interventions
- Drug: DE-117 ophthalmic solution
- First Posted Date
- 2016-07-04
- Last Posted Date
- 2017-11-20
- Lead Sponsor
- Santen Pharmaceutical Co., Ltd.
- Target Recruit Count
- 125
- Registration Number
- NCT02822729
A Pharmacokinetic Study of DE-117 Ophthalmic Solution in Healthy Adult Male Subjects - Phase I Study -
- First Posted Date
- 2016-01-08
- Last Posted Date
- 2016-06-29
- Lead Sponsor
- Santen Pharmaceutical Co., Ltd.
- Target Recruit Count
- 14
- Registration Number
- NCT02650063
- Locations
- 🇯🇵
CPC Clinical Trial Hospital, Medipolis Medical Research Institute, Kagoshima, Japan
A Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension -AYAME Study-
Phase 2
Completed
- Conditions
- Primary Open Angle GlaucomaOcular Hypertension
- Interventions
- Drug: DE-117 ophthalmic solution lowDrug: Placebo ophthalmic solutionDrug: DE-117 ophthalmic solution high
- First Posted Date
- 2015-12-08
- Last Posted Date
- 2017-11-20
- Lead Sponsor
- Santen Pharmaceutical Co., Ltd.
- Target Recruit Count
- 253
- Registration Number
- NCT02623738
Study of DE-108 Ophthalmic Solution in Patients Who Are Scheduled for Cataract Surgery
- First Posted Date
- 2015-10-12
- Last Posted Date
- 2017-10-12
- Lead Sponsor
- Santen Pharmaceutical Co., Ltd.
- Target Recruit Count
- 576
- Registration Number
- NCT02573610
- Locations
- 🇰🇷
Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of
🇰🇷Kim's eye Hospital, Seoul, Korea, Republic of
🇰🇷Kyungpook National University Hospital, Kyungpook, Korea, Republic of
Study of Methacholine Chloride Inhalation Challenge in Children With Bronchial Asthma
- First Posted Date
- 2014-03-27
- Last Posted Date
- 2017-03-29
- Lead Sponsor
- Santen Pharmaceutical Co., Ltd.
- Target Recruit Count
- 10
- Registration Number
- NCT02097537
- Locations
- 🇯🇵
Santen study sites, Osaka, Japan
Efficacy and Safety of Betamethasone Microsphere in Patients With Macular Edema Following Branch Retinal Vein Occlusion (HIKARI)
Phase 2
Completed
- Conditions
- Macular Edema Following Branch Retinal Vein Occlusion
- Interventions
- First Posted Date
- 2012-01-19
- Last Posted Date
- 2014-07-21
- Lead Sponsor
- Santen Pharmaceutical Co., Ltd.
- Registration Number
- NCT01512901
- Locations
- 🇰🇷
Santen study sites, Seoul, Korea, Republic of
Efficacy and Safety of Betamethasone Microsphere in Patients With Diabetic Macular Edema (TSUBASA)
Phase 2
Completed
- Conditions
- Diabetic Macular Edema
- Interventions
- First Posted Date
- 2011-08-08
- Last Posted Date
- 2014-07-21
- Lead Sponsor
- Santen Pharmaceutical Co., Ltd.
- Registration Number
- NCT01411254
- Locations
- 🇯🇵
Santen study sites, Osaka, Japan
Study of DE-114 Ophthalmic Solution in Patients With Allergic Conjunctivitis
Phase 3
Completed
- Conditions
- Allergic Conjunctivitis
- Interventions
- Drug: DE-114 ophthalmic solutionDrug: Placebo ophthalmic solution
- First Posted Date
- 2011-06-01
- Last Posted Date
- 2014-11-19
- Lead Sponsor
- Santen Pharmaceutical Co., Ltd.
- Target Recruit Count
- 87
- Registration Number
- NCT01363700
- Locations
- 🇯🇵
Santen study sites, Osaka, Japan
© Copyright 2025. All Rights Reserved by MedPath